Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845235 | 1.00 | HSD17B10 (0.60) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL30071406 | 0.87 | LMNA (0.47) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| SCHEMBL23368488 | 0.84 | HSD17B10 (0.58) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL24093933 | 0.84 | HSD17B10 (0.58) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL23213586 | 0.83 | KDM4E (0.62) | HSD17B10KDM4EHPGDALDH1A1LMNA | |
| SCHEMBL14631512 | 0.78 | HSD17B10 (0.67) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL3905353 | 0.78 | HSD17B10 (0.67) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL14487623 | 0.77 | HSD17B10 (0.61) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL3354341 | 0.76 | HSD17B10 (0.65) | HSD17B10GLAKDM4EALOX15HPGD | |
| SCHEMBL31481214 | 0.76 | HSD17B10 (0.65) | HSD17B10GLAKDM4EALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041729-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-4041729-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021070054-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370451-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, SAMHD1, POLR2H | HSD17B10 3059/4885GLA 2816/4885KDM4E 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.